Title |
Biologic monotherapy in the treatment of rheumatoid arthritis
|
---|---|
Published in |
Biologics: Targets & Therapy, May 2015
|
DOI | 10.2147/btt.s53361 |
Pubmed ID | |
Authors |
Jacqueline Detert, Pascal Klaus |
Abstract |
Biologics, possibly in combination with a conventional disease-modifying antirheumatic drug (DMARD) - preferably methotrexate (MTX), are used in accordance with the recommendations of the international rheumatological societies. However, in clinical practice, this recommendation is often problematic, as many rheumatologists know from personal experience. The quality of life of the patient is affected mainly by drug-induced intolerances (eg, MTX). Thus, the acceptance of the patient to treatment is often so inadequate that a discontinuation of the drug is necessary. In daily practice, approximately 30% of patients with biological therapy receive no concomitant DMARD according to the register data. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 2 | 25% |
Colombia | 1 | 13% |
Bulgaria | 1 | 13% |
United States | 1 | 13% |
Spain | 1 | 13% |
Unknown | 2 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 50% |
Practitioners (doctors, other healthcare professionals) | 3 | 38% |
Science communicators (journalists, bloggers, editors) | 1 | 13% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 76 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 14 | 18% |
Researcher | 12 | 16% |
Other | 11 | 14% |
Student > Doctoral Student | 9 | 12% |
Student > Master | 7 | 9% |
Other | 15 | 20% |
Unknown | 8 | 11% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 29 | 38% |
Pharmacology, Toxicology and Pharmaceutical Science | 16 | 21% |
Agricultural and Biological Sciences | 4 | 5% |
Biochemistry, Genetics and Molecular Biology | 4 | 5% |
Computer Science | 2 | 3% |
Other | 9 | 12% |
Unknown | 12 | 16% |